Equillium, Inc. (EQ)
NASDAQ: EQ · Real-Time Price · USD
0.5038
+0.1115 (28.42%)
At close: Apr 1, 2025, 4:00 PM
0.4830
-0.0208 (-4.13%)
After-hours: Apr 1, 2025, 4:27 PM EDT
Equillium Employees
Equillium had 44 employees as of December 31, 2023. The number of employees increased by 8 or 22.22% compared to the previous year.
Employees
44
Change (1Y)
8
Growth (1Y)
22.22%
Revenue / Employee
$933,977
Profits / Employee
-$183,341
Market Cap
17.94M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
EQ News
- 5 days ago - Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients - Benzinga
- 5 days ago - Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights - Business Wire
- 5 days ago - Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - Business Wire
- 7 weeks ago - Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis - Business Wire
- 4 months ago - Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates - Business Wire
- 4 months ago - Equillium to Present at the Stifel Healthcare Conference - Business Wire
- 5 months ago - Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer - Business Wire
- 5 months ago - Equillium Maintains Rights to Itolizumab Following Ono Partnership - Business Wire